Calidi Biotherapeutics Invites Investors to a Special Webinar
In an exciting opportunity for investors, Calidi Biotherapeutics Inc. (NYSE American: CLDI), a pioneering organization in the biotechnology sector, is hosting an exclusive webinar. This event promises to deliver valuable insights into the company’s groundbreaking work in the field of targeted antitumor virotherapies. It is scheduled to take place at 4:15 p.m. ET, marking an essential occasion for those interested in the future of cancer treatment.
Expert Presentation and Q&A Session
The webinar will be hosted by RedChip Companies and features key personnel from Calidi, including CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD. PhD. These experts will share in-depth information about Calidi's innovative cell-based delivery systems, designed to significantly enhance the treatment of various cancers.
Overview of Innovative Lead Programs
During the session, the presenters will discuss some of Calidi’s most promising lead programs. This includes CLD-400, which is specifically targeting metastatic cancers, as well as CLD-201 developed for advanced solid tumors, and CLD-101 aimed at high-grade glioma patients. Each program reflects Calidi's commitment to harnessing innovative technologies in the fight against cancer.
Interactive Q&A Opportunity
After the presentations, attendees will have the chance to engage directly with Calidi's leadership team during a live Q&A session. This interactive portion will allow participants to inquire further about the company’s research, development strategies, and future plans, fostering a deeper understanding of Calidi's commitment to advancing cancer therapies.
How to Register
Registering for the webinar is simple and free of charge. Interested individuals can sign up and join in on this informative session. It’s a great opportunity for investors and anyone interested in the latest advancements in cancer treatment.
About Calidi Biotherapeutics
Calidi Biotherapeutics is at the forefront of innovation in the immuno-oncology arena, utilizing its unique approaches to empower the immune system in the fight against cancer. The company develops advanced cell-based platforms that leverage allogeneic stem cells. These cells efficiently carry oncolytic viruses, which serve as a novel therapeutic strategy for treating challenging oncology situations, such as high-grade gliomas and a range of solid tumors.
The Dual Mechanism Approach
Calidi’s robust platform not only aims to deliver oncolytic viruses but also enhances their efficacy and safety for patients. Their preclinical efforts include enveloped virotherapies, designed to address disseminated solid tumors, showcasing a dual action approach to potentially mitigate or even prevent metastatic disease.
Headquarters and Further Information
Calidi Biotherapeutics maintains its headquarters in San Diego, California. With a dedication to advancing cancer therapies, the company is committed to providing innovative solutions in oncology. For anyone interested in learning more about Calidi and its research initiatives, additional information is readily accessible on the company’s official website.
Frequently Asked Questions
What is the primary goal of the Calidi Biotherapeutics webinar?
The primary goal is to share insights into the company's innovative therapies and engage with investors through a Q&A session.
Who are the featured speakers at the webinar?
The webinar will feature CFO Andrew Jackson and CSO Antonio F. Santidrian, who will discuss the company's strategic direction.
What specific programs will be highlighted during the event?
Prominent programs such as CLD-400, CLD-201, and CLD-101 will be discussed in detail.
How can I register for the webinar?
Registration is free and can be completed online through the designated registration link provided by Calidi Biotherapeutics.
Where is Calidi Biotherapeutics headquartered?
The company is headquartered in San Diego, California, focusing on advancing clinical-stage immuno-oncology solutions.
